Stock Events

Stock Events

Clinuvel Pharmaceuticals 

€5.48
0
-€0.06-1.12% Thursday 16:35

Statistics

Day High
5.49
Day Low
5.48
52W High
8.07
52W Low
5.31
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q4 2025
0.12
0.13
0.15
0.17
Expected EPS
0.16525896168235998
Actual EPS
0.11651557666699999

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UR9.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Icon
ICLR
Mkt Cap8.31B
ICON plc provides clinical research services to the pharmaceutical, biotechnology, and medical device industries, competing in the development and commercialization of dermatological treatments similar to Clinuvel's focus.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. is involved in the discovery, development, manufacture, marketing, sales, and distribution of biopharmaceutical products, including treatments in areas that overlap with Clinuvel's therapeutic focus.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products, competing in areas such as skin conditions and rare diseases.
Novartis
NVS
Mkt Cap297.35B
Novartis AG researches, develops, manufactures, and markets healthcare products in areas that compete with Clinuvel, including dermatology and rare diseases.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, including skin health products that compete with Clinuvel's portfolio.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson researches and develops, manufactures, and sells a broad range of products in the healthcare field, including competitive offerings in dermatology and rare diseases.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products directly competing in the dermatology and rare disease market segments targeted by Clinuvel.
AMGEN
AMGN
Mkt Cap189.22B
Amgen Inc. focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise, competing in the development of treatments for conditions that Clinuvel also targets.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including skin diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic diseases that overlap with Clinuvel's focus areas.

About

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Show more...
CEO
Dr. Philippe Jacques Wolgen M.B.A., M.D.
Employees
109
Country
Australia
ISIN
AU000000CUV3

Listings

MU
DE
UR9A.MU
STU
DE
UR9A.STU
STU
DE
UR9.STU
MU
DE
UR9.MU

0 Comments

Share your thoughts

FAQ

What is Clinuvel Pharmaceuticals stock price today?▼
The current price of UR9.STU is €5.48 EUR — it has decreased by -1.12% in the past 24 hours. Watch Clinuvel Pharmaceuticals stock price performance more closely on the chart.
What is Clinuvel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Clinuvel Pharmaceuticals stocks are traded under the ticker UR9.STU.
Is Clinuvel Pharmaceuticals stock price growing?▼
UR9.STU stock has fallen by -0.4% compared to the previous week, the month change is a -7.55% fall, over the last year Clinuvel Pharmaceuticals has showed a -8.4% decrease.
When is the next Clinuvel Pharmaceuticals earnings date?▼
Clinuvel Pharmaceuticals is going to release the next earnings report on September 01, 2026.
What were Clinuvel Pharmaceuticals earnings last quarter?▼
UR9.STU earnings for the last quarter are 0.12 EUR per share, whereas the estimation was 0.17 EUR resulting in a -29.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Clinuvel Pharmaceuticals have?▼
As of April 17, 2026, the company has 109 employees.
In which sector is Clinuvel Pharmaceuticals located?▼
Clinuvel Pharmaceuticals operates in the Health & Wellness sector.
When did Clinuvel Pharmaceuticals complete a stock split?▼
Clinuvel Pharmaceuticals has not had any recent stock splits.
Where is Clinuvel Pharmaceuticals headquartered?▼
Clinuvel Pharmaceuticals is headquartered in Melbourne, Australia.